Insulet Corp. (PODD) on Decifer

Decifer ranks PODD number 274 of 277 tracked names on durable business quality.

Why it ranks here

• It earns solid returns on the money it puts to work, around 14% and those returns have been improving and it turns most of its profit into real cash.
• Revenue is growing about 31% a year, profits are expected to grow 19%, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power, with profitability widening as it grows.
• It is riding an active market tailwind and has the balance sheet to fund its growth.
• And it returns cash to shareholders and its own insiders have been buying.
• Revenue growing 31% and 14% returns are strong but momentum of 0 out of 35 and no funded reason to grow remove the foundation for a growth bet.

The current read

The evidence on PODD points in two directions at once: the intelligence feed flags this name as connected to what is moving markets now, while a live market force pressures this name through its theme connection. Until one side gives way, treat the picture as unresolved rather than a clean story.

Themes

• GLP-1 & Metabolic Disease Wave: GLP-1 receptor agonists have demonstrated large-scale efficacy in obesity and diabetes, triggering a multi-hundred-billion-dollar demand and capex surge across pharma and diabetes-device makers.

Read the full PODD research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.